-

Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish

  • Dexcom provides more choice to users by launching Spanish-language capabilities for its mobile app for the best-selling real-time CGM in the world
  • Spanish-speaking patients can opt to use the Dexcom G6 app in their preferred language, eliminating a language barrier for optimal care

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1.10.1) or Android (v1.10.0) smart device.

Diabetes disproportionately impacts Latinos, and as of 2022, it is estimated that 11.8% of U.S. Latino adults have diagnosed diabetes.1 Furthermore, the CDC estimates that U.S. Latino adults have more than a 50% chance of developing Type 2 diabetes, with a greater risk of complication.2

“With a myriad of studies that point to language barriers in healthcare leading to miscommunication between patients and healthcare providers3 and a decrease in quality of care and patient safety, it’s important to provide access to diabetes information in a patient’s preferred language to improve health outcomes,” said Ana-Mari Calleja Carr, district business manager at Dexcom representing the South Florida region. “Launching the Dexcom G6 app in Spanish is a positive step toward improving health equity for individuals with diabetes who primarily speak Spanish.”

To access the Dexcom G6 mobile app in Spanish, users need to install the latest version of the app and set their compatible iOS (v1.10.1) or Android (v1.10.0) smartphone* language to Spanish (any dialect/region). The app will automatically display in Spanish as long as the phone language is set to Spanish.

“Being able to offer this powerful CGM technology to my Spanish-speaking patients in their preferred language can help them better understand their diabetes and be more proactive about managing their health,” said Dr. Rocio Harbison, MD, FACE, an endocrinologist who treats a large Spanish-speaking population. “CGM technology is one of the most powerful tools available for managing diabetes and this new development from Dexcom will help improve access for Spanish-speaking people who often have to navigate their health with limited Spanish-language tools.”

Dexcom G6 uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a compatible smart device* or receiver, giving patients real-time glucose data without the need to prick their finger. The system also offers customizable alerts and alarms to help avoid potentially dangerous low and high blood sugar events.

“It’s great to see that Dexcom invested in developing a Spanish-language app for patients,” said Siena Ruelas, a professional soccer player and Dexcom Warrior who has Type 1 diabetes. “This offering will help remove a significant barrier to accessing important glucose information and improve one’s ability to make critical health decisions.”

The Dexcom Follow app is not immediately available in Spanish but the functionality will be added in a future product update. For more information in Spanish on Dexcom G6, please visit Dexcom.com/ayuda.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

*For a list of compatible devices, visit www.dexcom.com/compatibility.

If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

1 https://www.diabetes.org/about-us/statistics/about-diabetes
2 https://www.cdc.gov/diabetes/library/features/hispanic-diabetes.html
3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201401/

© 2022 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

Dexcom, Inc.

NASDAQ:DXCM

Release Summary
Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish
Release Versions

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From Dexcom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom